There are three major classes of endocrine therapy drugs with different mechanisms of action used to treat and/or prevent ER + breast cancers, i.e., selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor down-regulators or degraders (SERDs). Here, CYP19A1 is linked to breast carcinoma.